| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445526 | European Journal of Cancer | 2012 | 9 Pages |
Abstract
Irinotecan has a significant anti-tumour activity and acceptable toxicity in patients with relapsed hepatoblastoma and therefore should be considered for the treatment of these patients. Exploration of the role of irinotecan in the initial treatment of hepatoblastoma is warranted.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
József ZsÃros, Laurence Brugières, Penelope Brock, Derek Roebuck, Rudolf Maibach, Margaret Child, Bruce Morland, Michela Casanova, Daniele Pariente, Claudia Paris, Beatriz de Camargo, Milind Ronghe, Arthur Zimmermann, Jack Plaschkes, Piotr Czauderna,